Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Up 4.4% – Should You Buy?

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)’s stock price rose 4.4% on Monday . The stock traded as high as $5.39 and last traded at $5.22. Approximately 1,545,002 shares traded hands during mid-day trading, a decline of 4% from the average daily volume of 1,602,808 shares. The stock had previously closed at $5.00.

Key Stories Impacting Perspective Therapeutics

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: B. Riley raised its price target from $11 to $13 and maintained a “Buy” rating — a sizeable upside projection that signals stronger sell‑side conviction in the company’s growth/clinical roadmap. B. Riley Price Target Raise
• Positive Sentiment: UBS raised its price target from $7 to $8 and kept a “Buy” rating, providing additional analyst support for upside potential. UBS Price Target Raise
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating with an $11 target — another vote of confidence from a major biotech analyst. Wedbush Rating Reaffirmation
• Positive Sentiment: Perspective announced that updated data for its lead radiopharmaceutical, [212Pb]VMT-α-NET, was accepted for poster presentation at AACR 2026 — this raises scientific visibility and could help commercial/regulatory momentum if the data remain favorable. The company previously reported encouraging anti‑tumor activity (76% without progression in a subset) and no dose‑limiting toxicities in interim analyses. AACR Presentation Acceptance
• Neutral Sentiment: The company is scheduled to release quarterly earnings this week — an event that can be a catalyst for volatility as investors reassess cash runway, R&D spend and trial progress. Earnings Release Date
• Neutral Sentiment: Perspective published full‑year 2025 results and business highlights; these filings provide more detail on cash, operating burn and program timelines that investors will parse for runway and dilution risk. Full‑Year 2025 Results
• Negative Sentiment: Royal Bank of Canada trimmed its target from $18 to $14 (still “Outperform”) — a downward revision that could moderate upside expectations and trigger short‑term profit‑taking. RBC Target Lowered
• Negative Sentiment: Clinical safety data include Grade 3+ treatment‑emergent adverse events in ~37.5% of patients (one transient Grade 4 reported); these safety signals may temper enthusiasm until larger cohorts and confirmatory data are available. Clinical Safety Details

Wall Street Analysts Forecast Growth

Several research firms have commented on CATX. B. Riley Financial upped their target price on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday. Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Wednesday. HC Wainwright raised their target price on Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Royal Bank Of Canada cut their target price on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, Piper Sandler started coverage on Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $12.50.

Perspective Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 5.17. The company’s 50-day moving average price is $4.30 and its two-hundred day moving average price is $3.43.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The company had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. Equities research analysts expect that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Aigen Investment Management LP acquired a new stake in Perspective Therapeutics during the 4th quarter worth about $28,000. Russell Investments Group Ltd. increased its position in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $31,000. AXQ Capital LP lifted its position in shares of Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after acquiring an additional 2,481 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in shares of Perspective Therapeutics in the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.